Yu Ranjie, Li Chengyi, Lin Xiaomei, Chen Qun, Li Jie, Song Li, Lin Lin, Liu Jingnan, Zhang Yan, Kong Wencui, Ouyang Xuenong, Chen Xiong
Department of Oncology, Fuzhou General Hospital of Nanjing Military Command, Fuzong Clinical College of Fujian Medical University, Fuzhou 350025, Fujian, China.
Department of Surgical Oncology, Affiliated Mindong Hospital of Fujian Medical University, Fuan 355000, Fujian, China.
Pathol Res Pract. 2017 Aug;213(8):964-968. doi: 10.1016/j.prp.2017.04.024. Epub 2017 May 4.
MYBL2 (B-MYB), a member of the MYB family of transcription factor genes, regulates the expression of genes in the process of tumorigenesis. Many studies have shown that MYBL2 is high expresssion in several human malignancies including pancreatic ductal adenocarcinoma (PDAC). However, its role in PDAC is still unclear. The present study is designed to investigate MYBL2 expression levels and prognostic significance in PDAC patients. We assessed MYBL2 expression level by immunohistochemistry in tumor tissues from 93 PDAC patients undergoing curative resection. The association of MYBL2 expression with clinicopathological parameters was evaluated by Pearson's chi-square (χ2) test, Fisher's exact test, and Spearman's rank. Kaplan-Meier survival analysis and Cox proportional hazards models were used to estimate the effect of MYBL2 expression on survival. The expression of MYBL2 was significantly higher in PDAC cells compared with adjacent non-cancerous tissues (P=0.000). The overexpression of MYBL2 in the tumor tissues was significantly correlated with a higher T classification (p=0.002), peri-neural invasion (PNI) (p=0.013) and vital status (p=0.045). Kaplan-Meier analysis indicated that high MYBL2 expression was significantly associated with shorter overall survival times in PDAC patients. Moreover, univariate and multivariate analysis confirmed MYBL2 expression (P=0.010), histological grade (P=0.001) as independent prognostic factors in PDAC. These results suggested that overexpression of MYBL2 might serve as a novel prognostic biomarker in PDAC patients.
MYBL2（B-MYB）是MYB转录因子基因家族的成员，在肿瘤发生过程中调节基因表达。许多研究表明，MYBL2在包括胰腺导管腺癌（PDAC）在内的几种人类恶性肿瘤中高表达。然而，其在PDAC中的作用仍不清楚。本研究旨在调查MYBL2在PDAC患者中的表达水平及预后意义。我们通过免疫组织化学评估了93例接受根治性切除的PDAC患者肿瘤组织中MYBL2的表达水平。采用Pearson卡方（χ2）检验、Fisher精确检验和Spearman秩相关分析评估MYBL2表达与临床病理参数的相关性。采用Kaplan-Meier生存分析和Cox比例风险模型估计MYBL2表达对生存的影响。与相邻的非癌组织相比，PDAC细胞中MYBL2的表达显著更高（P = 0.000）。肿瘤组织中MYBL2的过表达与更高的T分期（p = 0.002）、神经周围浸润（PNI）（p = 0.013）和生存状态（p = 0.045）显著相关。Kaplan-Meier分析表明，MYBL2高表达与PDAC患者较短的总生存时间显著相关。此外，单因素和多因素分析证实MYBL2表达（P = 0.010）、组织学分级（P = 0.001）是PDAC的独立预后因素。这些结果表明，MYBL2的过表达可能作为PDAC患者一种新的预后生物标志物。
